Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 43,700 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | -- | -- | |
| Jun 15, 2020 | Chief Science Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 1,446 | $11.14 | 520,807 | |
| Apr 01, 2020 | Chief Science Officer | Grant, award or other acquisition pursuant to Rule 16b-3(d) | Form 4 | 11,354 | -- | 522,253 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 6,300 | $8.61 | 527,455 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 29,148 | $6.10 | 556,603 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 17,652 | $5.13 | 574,255 | |
| Feb 12, 2020 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 63,356 | $11.01 | 510,899 | |
| Feb 12, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 6,300 | -- | 43,700 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.